Scarica l'app Stockscreener
2.09
6.28%
-0.14
Pre-mercato:
2.14
0.05
+2.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Precedente Chiudi:
$2.23
Aprire:
$2.23
Volume 24 ore:
4.28M
Relative Volume:
1.10
Capitalizzazione di mercato:
$622.79M
Reddito:
$38.03M
Utile/perdita netta:
$-146.40M
Rapporto P/E:
-4.0192
EPS:
-0.52
Flusso di cassa netto:
$-121.38M
1 W Prestazione:
-17.39%
1M Prestazione:
-19.15%
6M Prestazione:
-18.68%
1 anno Prestazione:
-52.93%
Intervallo 1D:
$2.06
$2.23
Intervallo di 1 settimana:
$2.06
$2.53
Portata 52W:
$2.06
$4.7499
Abcellera Biologics Inc Stock (ABCL) Company Profile
Nome
Abcellera Biologics Inc
Settore
Industria
Telefono
(604) 559-9005
Indirizzo
2215 YUKON STREET, VANCOUVER
Confronta ABCL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
2.09 | 622.79M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Ripresa | Piper Sandler | Overweight |
| 2023-02-28 | Iniziato | Cowen | Outperform |
| 2022-12-15 | Iniziato | Goldman | Buy |
| 2022-11-16 | Iniziato | Truist | Buy |
| 2021-12-21 | Iniziato | The Benchmark Company | Buy |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2021-01-05 | Iniziato | Berenberg | Buy |
| 2021-01-05 | Iniziato | Credit Suisse | Outperform |
| 2021-01-05 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | Stifel | Buy |
Mostra tutto
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
Abcellera stock hits 52-week low at $2.1 amid market challenges - Investing.com India
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Yahoo Finance
AbCellera at KeyBanc Forum: Strategic Moves in Antibody Discovery By Investing.com - Investing.com UK
AbCellera Stock: Burning Cash, Searching For 'Blockbusters' (NASDAQ:ABCL) - Seeking Alpha
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earni - GuruFocus.com
Thermopylae holdings acquires $742,242 in AbCellera shares By Investing.com - Investing.com South Africa
Thermopylae holdings acquires $742,242 in AbCellera shares - Investing.com India
Abcellera stock hits 52-week low at $2.20 amid market challenges - Investing.com Australia
AbCellera biologics director John Montalbano acquires $57,499 in shares By Investing.com - Investing.com South Africa
AbCellera biologics director John Montalbano acquires $57,499 in shares - Investing.com India
Independent Non-Employee Director of AbCellera Biologics Picks Up 66% More Stock - Simply Wall St
Ambarella, Builders Firstsource, Sherwin-Williams, AutoZone, AbCellera: Stock Moves That Shocked the Market - TipRanks
Director Makes Bold Move with Major Stock Purchase in AbCellera Biologics - TipRanks
Abcellera Biologics director Montalbano buys $140,568 in shares By Investing.com - Investing.com South Africa
Abcellera Biologics director Montalbano buys $140,568 in shares - Investing.com
Q1 Earnings Estimate for ABCL Issued By Bloom Burton - Defense World
Sanctuary Advisors LLC Decreases Stake in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics’ (ABCL) Hold Rating Reaffirmed at Benchmark - Defense World
Benchmark maintains Hold on AbCellera stock, no price target change - Investing.com
Benchmark maintains Hold on AbCellera stock, no price target change By Investing.com - Investing.com UK
Stifel Nicolaus Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat
AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
AbCellera Biologics (NASDAQ:ABCL) Reaches New 52-Week Low on Analyst Downgrade - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Earnings on Thursday - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
AbCellera Biologics’ Earnings Call: Transition Amid Challenges - TipRanks
Abcellera stock hits 52-week low at $2.33 amid market challenges - Investing.com India
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates - MSN
AbCellera Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2024 Earnings Call Transcript - Insider Monkey
AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ... - Yahoo Finance
AbCellera Biologics Reports 2024 Financial Results - TipRanks
Abcellera Biologics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AbCellera Reports Full Year 2024 Business Results - sharewise
Abcellera Biologics earnings beat by $0.01, revenue fell short of estimates - Investing.com
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript - MSN
AbCellera Biologics Reports 2024 Financial Results and Growth - TipRanks
AbCellera Biologics Inc. SEC 10-K Report - TradingView
AbCellera Biologics Q4 2024 Earnings Preview - MSN
Earnings Scheduled For February 27, 2025 - Benzinga
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earnings - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Trading Down 8.5%Here's What Happened - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Gap UpShould You Buy? - MarketBeat
This Healthcare Stock Rose Sharply On USPTO Issuance - The Globe and Mail
Abcellera Biologics Inc Azioni (ABCL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):